Brief: Eiger Receives Positive CHMP Opinion For Zokinvy As A Treatment For Hutchinson-Gilford Progeria Syndrome And Processing-Deficient Progeroid Laminopathies
20/05/2022 13:44
Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER RECEIVES POSITIVE CHMP OPINION FOR ZOKINVY AS A
TREATMENT
FOR HUTCHINSON-GILFORD PROGERIA SYNDROME AND
PROCESSING-DEFICIENT PROGEROID LAMINOPATHIES
* EIGER BIOPHARMACEUTICALS INC - BASED ON CHMP
RECOMMENDATION, A
DECISION BY EUROPEAN COMMISSION IS ANTICIPATED WITHIN ABOUT TWO
MONTHS
Source text for Eikon: ID:nPnc2DCXTa
Further company coverage: EIGR.O
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview